J&J plunges after Covid-19 vaccine gets FDA warning

Editor: Dhirendra Tripathi

investing. com – Johnson & Johnson (NYSE: JNJ) fell 0.6% on Tuesday. The U.S. Food and Drug Administration (FDA) has warned that the company’s Covid-19 vaccine increases the risk of a rare neurological disorder.

Known as Guillain-Barré syndrome (GBS), the disease causes the body’s immune system to attack the limits and cause temporary paralysis. More than one person goes completely straight, but in some cases the paralysis can be severe.

The FDA has found several cases of this type in millions of people who have received the J&J vaccine.

According to the Reuters report, a statement by the US Centers for Disease Control and Prevention (CDC) showed that most of the cases were seen in men aged 50 and over.

According to the FDA, 100 preliminary reports of GBS in vaccinated patients include 95 major events requiring hospitalization and a death.

According to Reuters, approximately 12.8 million people in the United States have received a single dose of J&J’s vaccine.

The J&J vaccine has faced more than one mania in the past. Incidents of blood clots have been seen, but the FDA said the benefits of the vaccine outweigh the risks. There were manufacturing issues at one of its facilities in Baltimore as well, and the FDA asked the company to discard the 60 million doses of Covid-19 vaccine made there.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button